Company Reports

3M reported second-quarter organic sales growth of 5.4% year over year. Management raised its full-year guidance for organic sales and earnings per share growth.

Estimating 3M's legal liabilities from producing per- and polyfluoroalkyl substances is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum reduce 3M's risks substantially. We remain concerned about 3M's incremental PFAS-related liabilities, but we think they're manageable in their current state. 3M continues to work through PFAS-related claims in individual states in the US, with a handful resolved thus far and many more on the docket.

3M reported first-quarter year-over-year sales growth of 1.3% on April 21. Management maintained its full-year guidance.

Estimating 3M's legal liabilities from producing per- and polyfluoroalkyl substances, or PFAS, is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum reduce 3M's risks substantially. We remain concerned over 3M's incremental PFAS-related liabilities, but we think they're manageable in their current state. 3M continues to work through PFAS-related claims in individual states in the US, with a handful resolved thus far and many more on the docket.

3M reported fourth-quarter year-over-year organic sales growth of 2% the morning of Jan. 20. The firm grew its top line 1.5% over the full year, driven by strength in 3M's safety & industrial segment.

3M grew third-quarter sales 3.2% organically year over year. With 170 basis points of operating margin improvement, EPS compounded 10% on an adjusted basis. Results were driven by strength in 3M's Safety & Industrial segment and the Americas region.

Estimating 3M's legal liabilities from producing per- and polyfluoroalkyl substances, or PFAS, is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum reduce 3M's risks substantially. We remain concerned over 3M's incremental PFAS-related liabilities, but we think they're manageable in their current state. 3M continues to work through PFAS-related claims in individual states in the US, with a handful resolved thus far and many more on the docket.

3M's sales grew 1.5% organically and its adjusted operating margin expanded nearly 300 basis points year over year. Results were driven by strength in 3M's safety & industrial segment and the Asia-Pacific region.

Estimating 3M's legal liabilities from producing per- and polyfluoroalkyl substances, or PFAS, is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum reduce 3M's risks substantially. We remain concerned over 3M's incremental PFAS-related liabilities, but we think they're manageable in their current state. 3M continues to work through PFAS-related claims in individual states in the US, with a handful resolved thus far and many more on the docket.

3M's sales declined 0.3% organically from last year but grew 1.5%, removing the impact of products containing PFAS. GAAP operating income declined over 6%, driven by weakness in 3M's transportation and electronics segment as sales of products containing PFAS are ceased.

Estimating 3M's legal liabilities from producing per- and polyfluoroalkyl substances, or PFAS, is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum reduce 3M's risks substantially. We remain concerned over 3M's incremental PFAS-related liabilities, but we think they're manageable in their current state.

3M reported fourth-quarter results the morning of Jan. 21, marking another quarter of essentially flat growth. We’ve raised our fair value estimate to $105 per share from $89 to reflect our more bullish long-term margin and revenue growth expectations. Our Uncertainty Rating remains Very High to reflect the potential outcomes of litigation against 3M surrounding per- and polyfluoroalkyl substances, leaving the company in 2-star territory.

Estimating 3M's legal liabilities from producing per- and polyfluoroalkyl substances, or PFAS, is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum reduce 3M's risks substantially. We remain concerned over 3M's incremental PFAS-related liabilities, but we think they're manageable in their current state.

Along with its third-quarter earnings release on Oct. 22, narrow-moat 3M raised the low end of its expected range for full-year adjusted earnings per share. However, organic sales declined 0.1% year over year in the quarter, stemming from product line adjustments in the wake of PFAS lawsuits, declining demand in the Europe, Middle East, and Africa region, and the cessation of operations in smaller countries. We maintain our $89 fair value estimate.

Narrow-moat 3M raised the lower end of its full-year adjusted earnings per share expectations, sending shares up over 6% premarket on July 26. However, net sales declined 0.5% year over year, mostly stemming from organic sales declines in the EMEA region led by weakness in 3M’s consumer segment. We maintain our fair value estimate at $89 per share.

After taking a fresh look at the old-world conglomerate, we’ve decreased 3M’s fair value estimate to $89 per share from $118 stemming from a slightly more bearish view on its cost of capital and growth prospects. We’ve maintained our narrow economic moat rating and Standard Capital Allocation Rating. Near term, 3M’s dividend and reinvestment capabilities should continue to be suppressed as the firm pays legal settlements from the environmental damage it has caused by manufacturing per- and polyfluoroalkyl substances, or PFAS.

Estimating 3M's legal liabilities from producing per- and polyfluoroalkyl substances, or PFAS, is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum reduce 3M's risks substantially. We remain concerned over 3M's incremental PFAS-related liabilities, but we think they're manageable in their current state.

Estimating 3M's legal liabilities is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum greatly reduce 3M's risks and is the right move for shareholders. While we remain concerned over 3M's incremental PFAS-related liabilities, we think they're manageable.

Narrow-moat-rated 3M released a first-quarter earnings report that exceeded our earnings expectations. Further, full-year 2024 guidance, excluding Solventum, came in better than we hoped. Consequently, we raised our fair value estimate by roughly 6% to $110. While we completely pegged sales during the quarter, adjusted operating margins materially surpassed what we hoped to see, with a difference of roughly 260 basis points to the upside. After reviewing management’s latest guidance, on a like-for-like basis, we’re expecting approximately $0.25 more of earnings per share in the back half of the year (or nearly $140 million of earnings through the remainder of the year). This is a positive result for shareholders because it suggests management’s restructuring efforts are finally taking root, coupled with material carryover benefits. Though the market price rose 5% during the trading day, we think the market still doesn’t fully appreciate the upside in the stock. Shareholders may find it prudent to continue holding the stock for potential capital appreciation.

Estimating 3M's legal liabilities is a highly uncertain exercise. While some believe these liabilities total greater than the firm's market capitalization, we think 3M's settlements and the spinoff of Solventum greatly reduce 3M's risks and is the right move for shareholders. While we remain concerned over 3M's incremental PFAS-related liabilities, we think they're manageable.